Tafinlar + Mekinist, Companion Dx Approved for BRAF V600E–Mutant Metastatic NSCLC

Dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) with Oncomine Dx Target Test ...

JUNE 23, 2017